Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-09 DOI:10.2217/pme-2021-0088
Glenda Hoffecker, Genevieve P Kanter, Yao Xu, William Matthai, Daniel M Kolansky, Jay Giri, Sony Tuteja
{"title":"Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.","authors":"Glenda Hoffecker,&nbsp;Genevieve P Kanter,&nbsp;Yao Xu,&nbsp;William Matthai,&nbsp;Daniel M Kolansky,&nbsp;Jay Giri,&nbsp;Sony Tuteja","doi":"10.2217/pme-2021-0088","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To determine if interventional cardiologists' knowledge and attitudes toward pharmacogenetic (PGx) testing influenced their antiplatelet prescribing decisions in response to <i>CYP2C19</i> results. <b>Materials & methods:</b> Surveys were administered prior to participating in a randomized trial of <i>CYP2C19</i> testing. Associations between baseline knowledge/attitudes and agreement with the genotype-guided antiplatelet recommendations were determined using multivariable logistic regression. <b>Results:</b> 50% believed that PGx testing would be valuable to predict medication toxicity or efficacy. 64% felt well informed about PGx testing and its therapeutic application. However, PGx experience, knowledge, nor attitudes were significantly associated with agreement to genotype-guided antiplatelet recommendations. <b>Conclusion:</b> Cardiologists' knowledge and attitudes were not associated with <i>CYP2C19-</i>guided antiplatelet prescribing, but larger studies should be done to confirm this finding.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"41-49"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To determine if interventional cardiologists' knowledge and attitudes toward pharmacogenetic (PGx) testing influenced their antiplatelet prescribing decisions in response to CYP2C19 results. Materials & methods: Surveys were administered prior to participating in a randomized trial of CYP2C19 testing. Associations between baseline knowledge/attitudes and agreement with the genotype-guided antiplatelet recommendations were determined using multivariable logistic regression. Results: 50% believed that PGx testing would be valuable to predict medication toxicity or efficacy. 64% felt well informed about PGx testing and its therapeutic application. However, PGx experience, knowledge, nor attitudes were significantly associated with agreement to genotype-guided antiplatelet recommendations. Conclusion: Cardiologists' knowledge and attitudes were not associated with CYP2C19-guided antiplatelet prescribing, but larger studies should be done to confirm this finding.

介入心脏病专家对药物遗传学检测的态度及其对抗血小板处方决策的影响。
目的:了解介入心脏病医师对药物遗传学(PGx)检测的知识和态度是否会影响其CYP2C19检测结果对抗血小板处方的影响。材料与方法:在参加CYP2C19检测的随机试验之前进行调查。使用多变量逻辑回归确定基线知识/态度与基因型指导抗血小板建议的一致性之间的关联。结果:50%的人认为PGx检测对预测药物毒性或疗效有价值。64%的人对PGx检测及其治疗应用知情。然而,PGx的经验、知识和态度与基因型指导抗血小板建议的一致性显著相关。结论:心脏病专家的知识和态度与cyp2c19指导的抗血小板处方无关,但需要进行更大规模的研究来证实这一发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信